
Following his presentation at Winter Clinical Miami, Del Rosso spoke to Dermatology Times about the current treatment landscape of psoriasis.

Following his presentation at Winter Clinical Miami, Del Rosso spoke to Dermatology Times about the current treatment landscape of psoriasis.

In an interview with Dermatology Times, Del Rosso shared the latest in the treatment landscape for patients with Darier disease.

Del Rosso outlined new and off-label therapies for the disease that he shared in his presentation at Winter Clinical Miami.

In an interview with Dermatology Times, Del Rosso gave insight on off-label therapies that could be used to treat granuloma annulare.

James Del Rosso, DO, explored the treatment landscape and the importance of regular eye exams for patients with AD.

As a part of his presentation at Winter Clinical Miami, Del Rosso discussed new and emerging therapies for acne vulgaris.

James Del Rosso, DO, shared insights on existing and upcoming therapies for seborrheic dermatitis.

In his presentation at Winter Clinical Miami, Del Rosso covered new and emerging therapies as well as successful off-label uses.

Three posters supporting VP-315's treatment efficacy and outcomes were presented at the Winter Clinical Miami conference.

The 2-GEP test is made of 2 biomarkers, LINC00518 and PRAME.

Among the many sessions to be held at the Winter Clinical Miami 2024 Conference in Miami Beach, Florida, several Dermatology Times Editorial Advisory Board members are preparing to share their knowledge and insights.

Click here to answer our poll about the upcoming conference.

Study participants saw a rapid decrease in inflammatory lesions with the once-daily antibiotic, antibacterial, and retinoid gel.

From topical antibiotics like clindamycin to biologic injectables like adalimumab to surgical options like deroofing, treatment for HS can come in many forms.

Emmy Graber, MD, MBA, covered it all in her Winter Clinical Miami talk, offering take-home pearls via patient case studies.

With now more than 6 months of real-world use for baricitinib available, what challenges still remain for the alopecia areata treatment and what other agents are on the horizon?

Treatment is not mandatory and, in fact, clinicians are still without an FDA-approved treatment option, but parents often insist on some sort of action.

Topicals, orals, biologics—Armstrong’s Winter Clinical Miami presentation focused on new treatment options for patients with psoriasis with an emphasis on real-world observations.

Alexandra Golant, MD, and Seemal Desai, MD, weigh the pros and cons of each treatment option for atopic dermatitis, considering mechanism of action, efficacy, and safety. Which will emerge victorious?

“So much new in the world of pediatric dermatology—new and novel treatments for atopic dermatitis, hemangiomas, childhood blistering diseases, warts. We are practicing during the Golden Age of dermatology,” Swanson says.

The proportion of patients who achieved a SALT score < 10 jumped from 24.9% at 36 weeks to 28.9% at 52 weeks in the BARI 4-mg arm and 11.8% to 15.3% in the BARI 2-mg arm.

When evaluating treatment options for patients with psoriasis, rosacea, or eczema, clinicians should employ a top-down approach and remember to consider topical therapies.

Five days of treatment with the topical therapy measurably improved symptoms and emotional/functional impact for patients with actinic keratosis at week 8.

“We're going to talk about medical hair loss in terms of diagnosis and treatment and really try to make it very easy,” Leavitt says.

From deucravacitinib to roflumilast to tralokinumab and everything in between, James Del Rosso, DO, previews his upcoming Winter Clinical Miami session on new therapies.

“It's always a fun, vibrant educational session. We learn tips and advice, and it really is for any injector, both novice [and] advanced. You learn a lot of information,” Ablon says.

“A lot of our colleagues are just getting used to the new biologics for atopic dermatitis like tralokinumab and dupilumab, which have really been breakthroughs in the treatment of atopic dermatitis,” Lebwohl, one of the co-founders of the Fall and Winter Clinical meetings, says.

With an emphasis on real-world applicability and actionable pearls, clinicians gather in Miami to kick off the newest addition to the Fall and Winter Clinical meeting lineup.

Mark Nestor, MD, PhD, a co-director of the Winter Clinical Miami meeting, promises attendees a hands-on learning experience with real-world applicability.

Click here to answer this week's poll.